

opSens

Measure... Improve



CORPORATE PROFILE • Opsens is a leading developer, manufacturer and supplier of a wide range of fiber optic sensors and associated signal conditioners based on proprietary patent and patent-pending technologies. Opsens sensors provide long-term accuracy and reliability in the harshest environments. Opsens provides sensors to measure pressure, temperature, strain and displacement to original equipment manufacturers (OEM) and end users in the oil and gas, medical, transformers, and laboratories fields. Opsens provides complete technical support, including installation, training and after-sales service.


INVESTMENT HIGHLIGHTS

- **Significant growth opportunity**
driven by increased need to measure temperature and pressure in SAGD oil sands wells.
- **Sensor technology proven**
in oil sands installation, differentiating us from R&D companies.
- **Widely adaptable technology**
giving us diverse growth opportunities in three strategic markets.
- **High-margin potential**
supported by recurring revenue streams from regular sensor replacement.
- **Financial position**
sufficient to commercialize our products in oil and gas and medical market.

FINANCIAL HIGHLIGHTS

Quarterly Revenue

(\$'000's)



Key Events in 2008

- Completed first installation of OPP-W fiber optic sensor for major oil sands operator.
- Raised gross proceeds of C\$3.8 million from private placement of units at \$0.80 each.
- Completed the acquisition of Inflo Solutions Inc., renamed Opsens Solutions Inc., to spearhead the company's operations in the oil and gas market.
- Records annual revenue increase of 250%, to \$2.8 million.
- BAE Systems, leader in the aerospace and defence industry, orders RadSens-type signal conditioners and fiber optic temperature sensors.
- Receives order worth more than \$300,000 from Japanese maker of medical devices for Opsens' LifeSens signal conditioners and pressure sensors.
- Receives \$400,000 order from European medical technology customer for its LifeSens OEM boards.
- Two major oil sands operators order conventional sensors worth more than \$300,000.
- In 1Q 2009, receives order to install OPP-W fiber optic sensors in three wells at Nexen Inc.'s Long Lake SAGD joint-venture project.

MESSAGE TO OUR SHAREHOLDERS

2008 was a pivotal year for Opsens. Your company maintained its focus on its business plan and we are proud to report that we reached some important milestones this year, and brought the company another step closer to its goal of becoming a major monitoring-solutions provider.

OIL AND GAS

Our oil and gas operations got a boost early in fiscal 2008, with the acquisition of Inflo Solutions, a company specializing in the design and installation of reservoir surveillance systems using optical and conventional sensors for the oil and gas industry. This independent unit, now called Opsens Solutions Inc., is an essential element in our expansion plan for the oil and gas market.

Opsens Solutions' most promising product is the OPP-W fiber optic sensor for continuous pressure and temperature measurement in very harsh environments, such as the oil sands. At temperatures up to 300 degrees Celsius, the sensor is designed for use in the Steam Assisted Gravity Drainage (SAGD) production process. SAGD is a method in which crude oil sands are heated by injecting steam into pipes below the earth's surface in order to reduce viscosity and extract crude oil.

With our new presence in Edmonton, Opsens has gained specific expertise in design and installation, allowing the company to offer integrated monitoring services of wells and reservoirs directly to its customers. Needless to say, Opsens Solutions is driving our aggressive commercialization efforts into Western Canada's multi-billion dollar oil sands market.

A PROVEN TECHNOLOGY

I am very proud to say that Opsens reached a significant milestone in fiscal 2008 with the successful first installation of two OPP-W sensors in two wells using the SAGD process. To optimize oil sands production, well operators need to continuously monitor pressure and temperature measurement at high temperatures. Opsens has been refining its OPP-W sensors for this use for the past several years, and undertook extensive in-house testing. We can now say, after several months of measurements in operating wells more than 600 meters below ground, that our OPP-W is a *proven* technology, a significant differentiator from our competitors. This success makes us optimistic about our prospects for fiscal 2009.

OTHER MARKETS

The 250% growth in revenue in fiscal 2008 is a mark of the growing acceptance our customers are showing of our products in each of our markets, including medical devices, laboratory and high-powered transformers.

In medical devices, we made significant steps forward. We are working closely with a leader in the medical instruments market to supply LifeSens OEM signal conditioners, which use white-light polarization interferometry technology (WLPI). That company is integrating our fiber optic sensors into its device to measure human blood pressure. A single-use optical pressure sensor, being developed in house, would also create recurring revenues in our medical device segment.

We notably increased revenues from the laboratory and high-powered transformers markets by adding new functionality to our fiber optic signal conditioners, as well as delivering high-quality sensors. In the laboratory market, we received an order from BAE Systems, a world leader in the aerospace industry, and in the transformer market, we delivered some units in Asia, expanding our distribution network.

OTHER EVENTS

Another 2008 achievement was the certification of our company as being ISO 9000:2001 compliant. Our team put a lot of effort into achieving that milestone, which assures our customers that we will deliver only the finest quality product, essential for any technology company such as Opsens.

On the financial side, we concluded a private placement of units for \$3.8 million at \$0.80 a unit, which each comprised one share and half of a warrant. The financing provides us with cash to support our expansion in 2009.

LOOKING TO 2009

2009 already looks promising to us, despite the challenging economic environment. We expect our Opsens Solutions unit to secure orders from new oil sands clients, and are targeting an order to install our technology in a full pad of wells. Our products are designed to save producers money and increase their output, all the more important in the current market. The order we received from Nexen Inc. in the first quarter confirms that customers see our technology as a valuable means to optimize production.

We will be introducing new sensors for measuring multiple parameters in the well to better help maximize oil recovery from producing fields.

We are confident that in fiscal 2009 we will realize major achievements in all of our segments, but in particular we believe that our unique pressure sensor for SAGD optimization will ultimately become the *standard* in high-temperature pressure measurement for all the SAGD fields.

Looking to our medical, laboratories and transformers markets, we will continue in 2009 to increase our efforts at the world-wide commercialization of our products.

Finally, I would like to thank our customers for their confidence in the products and expertise we offer, as well as our employees for their expertise and dedication which were vital in reaching this year's achievements. The counsel and experience of our directors continue to be key ingredients in our growth and creation of shareholder value. I also wish to thank all investors for their trust in the Opsens team.

(s) Pierre Carrier

Chairman of the Board, President and CEO

MANAGEMENT DISCUSSION & ANALYSIS

Annual report for shareholders

Fiscal year ended August 31, 2008

The following comments are intended to provide a review and analysis of the operating results and financial position of Opsens Inc. as of August 31, 2008, and for the fiscal year ended this date in comparison with the fiscal year ended August 31, 2007. They should be read and interpreted in conjunction with the audited financial statements as well as the accompanying notes as of August 31, 2008.

Unless stated otherwise, the interim Management Discussion and Analysis has been prepared in accordance with Canadian Generally Accepted Accounting Principles (GAAP) on a consolidated basis. This document was prepared on November 6, 2008. All amounts are in Canadian dollars unless otherwise noted.

This report contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of our future results, and actual results could differ significantly from those foreseen by such statements due to several factors, including economic conditions, capital expenditures in the measuring instrument sector, currency exchange rate variation, and our ability to manage Opsens successfully under these uncertain conditions. Consequently, the reader should not place undue reliance on these forward-looking statements. These forward-looking statements are only valid as at the date of this document. The Company is under no obligation to revise or update these forward-looking statements in order to reflect the events or circumstances that occur after the date of this analysis except when it is required by law.

CORPORATE OVERVIEW

Opsens Inc. (the “Company”) is a leading developer, manufacturer, and supplier of a wide range of fiber optic sensors and associated signal conditioners based on proprietary patented and patent-pending technologies. Opsens sensors provide long-term accuracy and reliability in the harshest environments. Opsens provides sensors to measure pressure, temperature, strain, and displacement to original equipment manufacturers (OEM) and directly to end-users in the oil and gas, medical instrumentation, high-power transformers, and scientific and military laboratory fields. Opsens offers technical services, such as on-site installation, training, and turnkey fiber optic systems.

Opsens holds three (3) patents and three (3) pending patents covering its products and technology provided to its markets, giving the Company freedom to operate on these markets. With its patented technologies and highly recognized expertise, Opsens meets consumer needs in the medical, oil and gas, high-power transformers, and scientific laboratory markets. Since December 11, 2007, activities in the field of oil and gas have been performed by the wholly-owned subsidiary Opsens Solutions Inc. (“Opsens Solutions”), formerly Inflo Solutions Inc.

VISION, STRATEGY, AND OUTLOOK

The worldwide market for fiber optic and conventional is a multi-billion dollar market. The Opsens sales and marketing strategy aims to provide solutions for the various current niche markets and develop new specific markets. The Company's expertise, know-how, and patented technology are the keys to new production techniques improving the reliability of measuring equipment. Also, the Opsens production technique called MEMS (Micro-Electro-Mechanical-System) encourages penetration into markets traditionally occupied by conventional sensors through higher production volumes and reduced manufacturing costs.

During fiscal 2009, Opsens expects its revenues from product sales to continue to grow compared to the comparative fiscal year in the oil and gas, medical devices, high-power transformers, and scientific and military laboratory sectors. The testing of the OPP-W sensor for the oil & gas during fiscal 2008 and greater maturity of our products, particularly in the medical sector, are major elements that will contribute significantly to increased revenues. Despite lower price of oil which could affect negatively investment in oil and gas, we perceive that lower oil and gas price will cause producers to look for optimization on operations and encourage mid-term commercialization for the OPP-W sensor.

Disclosures in volatile and uncertain times in the financial markets

In the current environment, Opsens continues to execute its business plan, targeting revenue growth in its four strategic sectors. The company continues to invest in human resources to provide its clients with top quality products and services. Given the controls in place in each of Opsens' units, the company doesn't at this point need to take any unusual measures. The current period of uncertainty and volatility has not required the company to change its method of dealing with credit, since Opsens' clients are primarily businesses with strong capitalization, distributors and government-related agencies.

As for recent currency fluctuations, an appreciating American dollar against the Canadian dollar generally favors sales figures and gross margins, since most of Opsens' sales are made in U.S. dollars.

Regarding cash management, the private placement that Opsens completed in 2008 gives the company the financial resources necessary to operate for the next year. The company has not changed its cash management strategy, which aims to protect its financial assets and defer spending that isn't essential to enacting Opsens' business plan in the near to medium term. If Opsens did need to raise money in the future, success would depend on revenue growth.

The accounting estimates used in the financial statements for the year ended August 31, 2008 were not modified for the current uncertain economic environment. These items are receivable tax credits, provisions for contractual guarantees and assumptions tied to the fair value of share options and warrants. Management doesn't anticipate an impact on the company's accounting estimates for fiscal 2009.

SELECTED CONSOLIDATED FINANCIAL DATA

(In thousands of dollars, except for information per share)	Fiscal year ended August 31, 2008	Fiscal year ended August 31, 2007	Fiscal year ended August 31, 2006
	\$	\$	\$
Sales	2,844	813	691
Partnership revenues	-	-	231
Revenues	2,844	813	922
Cost of sales	1,432	639	362
Gross margin	1,412	174	560
Administrative expenses	984	623	309
Marketing expenses	731	825	434
R&D expenses	699	591	363
Financial expenses (income)	(58)	(9)	143
Stock option-based compensation	253	345	-
Amortization of property, plant and equipment	100	72	63
Amortization of intangible assets	40	18	13
Write-off of intangible assets	-	12	-
Amortization of deferred financing fees	-	10	5
Class A retractable shares increase in value	-	-	273
	2,749	2,487	1,603
Loss before income taxes	(1,337)	(2,313)	(1,043)
Income taxes	-	-	-
Net loss	(1,337)	(2,313)	(1,043)
Net loss per share - Basic	(0.04)	(0.08)	(0.05)
Net loss per share - Diluted	(0.04)	(0.08)	(0.05)

(In thousands of dollars)	As at	As at	As at
	August 31, 2008	August 31, 2007	August 31, 2006
	\$	\$	\$
Current assets	5,462	2,543	1,172
Total assets	6,852	3,029	1,610
Current liabilities	770	541	889
Long-term debt	253	499	623
Class A retractable shares	-	-	773
Shareholders' equity	5,829	1,989	(675)

No dividend was declared per share for each share class.

On October 3, 2006, Opsens completed a qualifying transaction under the rules of the TSX Venture Exchange Corporate Finance Manual. On April 8, 2008, the Company completed a private placement of 4,711,126 units at a price of \$0.80 per unit for gross proceeds of \$ 3,768,901.

SUMMARY OF CONSOLIDATED QUARTERLY RESULTS

The summary below presents the periods in which Opsens published unaudited interim financial statements.

(In thousands of dollars)	Three-month period ended August 31, 2008	Three-month period ended May 31, 2008	Three-month period ended February 29, 2008	Three-month period ended November 30, 2007
	\$	\$	\$	\$
Revenues	748	890	637	569
Net loss for the period	228	359	403	347
Net loss per share - Basic	(0.01)	(0.01)	(0.01)	(0.01)
Net loss per share - Diluted	(0.01)	(0.01)	(0.01)	(0.01)

(In thousands of dollars)	Three-month period ended August 31, 2007	Three-month period ended May 31, 2007	Three-month period ended February 28, 2007	Three-month period ended November 30, 2006
	\$	\$	\$	\$
Revenues	187	187	266	174
Net loss for the period	531	700	520	562
Net loss per share - Basic	(0.02)	(0.02)	(0.02)	(0.02)
Net loss per share - Diluted	(0.02)	(0.02)	(0.02)	(0.02)

The acquisition of Inflo Solutions (See the *Strategic Acquisition and Development of New Products* section) on December 11, 2007, stimulated sales in the oil and gas sector beginning in the second quarter of fiscal year 2008.

Usually, the Company's industry and its revenues are affected very little by seasonal fluctuations. These fluctuations will become more significant as the weighting of sales in the oil and gas sector increases, since business activity is generally greater in the winter quarters for this sector.

FOURTH QUARTER 2008

For the fourth quarter ended August 31, 2008, the Company recorded a net loss of \$228,000 or \$0.01 per share. For the same quarter in fiscal year 2007, the loss was \$531,000 or \$0.02 per share. The decreased loss during the fourth quarter of fiscal year 2008 is explained in particular by an increase in revenues, the gross margin rate, the gross margin and financial income. Seasonal fluctuations and year-end adjustments had no impacts on operating revenues and net loss for fourth quarter 2008.

Revenues totalled \$748,000 for the three-month period ended August 31, 2008, compared to \$187,000 for the corresponding period in 2007. The strong growth in revenues was generated primarily by increased sales in the oil and gas, medical, and scientific and military laboratories sectors.

Administrative expenses amounted to \$319,000 for the three-month period ended August 31, 2008, compared to \$189,000 for the same period in 2007. This increase was mainly due to the administrative expenses generated by the new subsidiary Opsens Solutions and a rise in employment levels of \$60,000.

Marketing expenses were \$179,000 and \$165,000 respectively for the fiscal years ended August 31, 2008 and 2007. This increase was primarily caused by the \$54,000 increase in consulting fees and the overall decrease in other expenses.

R&D expenses totalled \$165,000 for the fiscal year ended August 31, 2008, compared to \$110,000 for the same period in 2007. This increase resulted from higher employment levels and a decrease in tax credits.

PERFORMANCE INDICATORS

In order to evaluate the Company's performance and generate long-term value for its shareholders, the Company has identified the following financial and non-financial performance indicators:

- 1) Distribution, sales, and long-term recurring revenues;
- 2) Products and innovation;
- 3) Short-term financial performance and cash flows;
- 4) Strategic acquisitions and development of new projects.

FISCAL YEARS ENDED AUGUST 31, 2008 AND 2007

DISTRIBUTION, SALES, AND LONG-TERM RECURRING REVENUES

(In thousands of dollars except for percentage data figures)	Fiscal year ended August 31, 2008	Fiscal year ended August 31, 2007
	\$	\$
Revenues	2,844	813
Growth rate (%)		250
Gross margin	1,412	174
Growth rate (%)		710

The Company generated \$2,844,000 in sales for the fiscal year ended August 31, 2008, compared to \$813,000 for the comparative fiscal year, registering an increase of 250%. The increased sales for fiscal year 2008 were generated by

organic growth in the medical device, scientific and military laboratory, and high-power transformers market of more than \$1,200,000 in addition to growth through the acquisition of a wholly-owned subsidiary based in Edmonton dedicated to the oil and gas market. Sales within the oil and gas market reached nearly \$800,000 (\$207,000 accounted for within the Opsens Inc. reportable segment) for fiscal year 2008.

The gross margin rate and the gross margin on product sales increased for the fiscal year ended August 31, 2008, in relation to the previous fiscal year, as the company realized economies of scale. The increase was generated by the strong weighting, in relation to total sales, of the scientific and military laboratory market, a market where the generated margin is high. The gross margin rate obtained during fiscal year 2008 is within the minimum expected target of 40%. As at August 31, 2008, the backlog amounted to \$295,000.

Given that a large proportion of the Company's revenue is generated in US dollars, while most costs are priced in Canadian dollars, fluctuation in the exchange rate affects revenue. For the fiscal year ended August 31, 2008, the average exchange rate was less than the previous year, which increased sales by \$239,000 for the fiscal year ended August 31, 2008.

Market acceptance of fiber optic sensors is increasing in various sectors. Consequently, some sectors, such as high-power transformers, are seeing additional competition. To face this competition, Opsens is working to highlight the performance characteristics of its products compared to competitors.

PRODUCTS AND INNOVATION

The Company is constantly working to improve its position in terms of intellectual property and what it can offer to its customers. During the fiscal year ended August 31, 2008, Opsens emphasized the continuous improvement of its existing product line and concentrated on its products intended for the medical devices and oil and gas markets. The Company's R&D strategy involves focusing its new product development efforts toward markets with very high potential. The oil and gas market is a concrete example of the application of this strategy.

R&D expenses increased to \$699,000 in FY 2008 from \$591,000 a year earlier. The change in R&D expenses during the period was generated mainly by increased employment levels.

SHORT-TERM FINANCIAL PERFORMANCE AND CASH FLOWS

Net loss

Reconciliation of EBITDA to the Annual Results

(In thousands of dollars)	Fiscal year ended August 31, 2008	Fiscal year ended August 31, 2007	Fiscal year ended August 31, 2006
	\$	\$	\$
Net loss for the period	(1,337)	(2,313)	(1,043)
Financial expenses (income)	(58)	(9)	143
Amortization of property, plant, and equipment	100	72	63
Amortization of intangible assets	40	18	13
Write-off of intangible assets	-	12	-
Amortization of deferred financing fees	-	10	5
Increase in the value of class A retractable shares	-	-	273
EBITDA ¹	(1,255)	(2,210)	(546)
Stock-based compensation costs	253	345	-
EBITDA before stock-based compensation costs	(1,002)	(1,865)	(546)

(1) The Company uses only one financial measure that is not consistent with Canadian GAAP, namely earnings before interest, income taxes, depreciation and amortization (EBITDA). Such a measure is used because management believes that it provides meaningful information about the Company's performance and operating results. Such a non-GAAP measure has no standardized meaning as prescribed by GAAP and is not necessarily comparable to similarly titled measures presented by other companies. Accordingly, it should not be considered independently of other figures.

For the fiscal year ended August 31, 2008, net loss totalled \$1,337,000, compared to \$2,313,000 for the fiscal year ended August 31, 2007. This decrease in net loss as well as the EBITDA before stock-based compensation costs for fiscal 2008 compared with a year earlier mainly reflects the increase in sales and gross margin combined with a \$262,000 increase in other expenses.

Fiscal 2009 results will be strongly influenced by product sales volume. The expansion of marketing activities within the oil and gas market following the OPP-W installations in 2008 should contribute to the increase in EBITDA.

Information by reportable segments

The company's reportable segments are strategic business units managed separately, as one is focused on developing, producing, and supplying fiber optic sensors (Opsens Inc.) while the other (Opsens Solutions) specializes in the marketing and installation of optical and conventional sensors for the oil and gas industry.

	2008			2007		
	Opsens			Opsens		
	Opsens Inc.	Solutions	Total	Opsens Inc.	Solutions	Total
	\$	\$	\$	\$	\$	\$
External sales	2,249,000	595,000	2,844,000	813,000	-	813,000
Internal sales	4,000	87,000	91,000	-	-	-
Amortization of property, plant and equipment	95,000	5,000	100,000	72,000	-	72,000
Amortization of intangible assets	20,000	20,000	40,000	30,000	-	30,000
Financial expenses	(72,000)	14,000	(58,000)	(9,000)	-	(9,000)
Income taxes	-	-	-	-	-	-
Net income (loss)	(1,232,000)	(105,000)	(1,337,000)	(2,313,000)	-	(2,313,000)
Acquisition of property, plant and equipment	270,000	45,000	315,000	142,000	-	142,000
Acquisition of intangible assets	38,000	-	38,000	74,000	-	74,000

The annual performance of the Opsens Inc. operating unit showed a sharp increase in revenues.

The Opsens Solutions operating unit began to generate earnings for the consolidated financial statements beginning December 11, 2007. This sector's performance contributed positively to sales growth while achieving major milestones for the Company's future, i.e. the successful installation of the OPP-W sensor within two wells operated with the Steam Assisted Gravity Drainage (SAGD) technology.

These operating units generate revenue in various geographic segments as follows:

	2008	2007
	\$	\$
Revenue by geographic sector		
Canada	652,000	27,000
United States	934,000	316,000
Germany	417,000	229,000
United Kingdom	285,000	50,000
Other	556,000	192,000
	2,844,000	813,000

Revenue is attributed to geographic segments based on the customers' location.

Capital assets, which include property, plant and equipment and intangible assets, are all located in Canada.

During the fiscal year ended August 31, 2008, revenues from three customers individually represented more than 10% of the Company's total revenues, i.e. approximately 18.09% (Opsens Solutions reportable segment), 17.62% (Opsens Inc. reportable segment) and 13.09% (Opsens Inc. reportable segment). For the fiscal year ended August 31, 2007, revenues from one customer represented 28.11% of the Company's total revenues.

Administrative expenses

Administrative expenses were \$984,000 for the fiscal year ended August 31, 2008, compared to \$623,000 for fiscal year 2007.

Administrative expenses increased mainly due to the administrative expenses generated by the new subsidiary Opsens Solutions and a rise in employment levels. In fiscal year 2009, administrative expenses will continue to increase, particularly in light of the expansion of the headquarters and the full-scale increase in expenses to support the anticipated growth in sales.

Sales and marketing expenses

Sales and marketing expenses decreased by \$94,000 to \$731,000 for the fiscal year ended August 31, 2008, compared to \$825,000 for fiscal year 2007.

This decrease is explained mainly by the reduced conference participation expenses. Sales and marketing expenses for the next fiscal year should increase in relation to the previous year, given the expected deployment of our sales and marketing activities at our Quebec installations as much as at our Edmonton installations.

Financial income (expenses)

Financial income was \$58,000 for the fiscal year ended August 31, 2008, compared to \$9,000 for the previous year. The increased financial income during fiscal year 2008 was the direct consequence of the exchange rate gain resulting from the appreciation of the American dollar against the Canadian dollar, particularly during the last quarter of the fiscal year.

Financing activities cash flow

Private placement

On April 8, 2008, the Company completed a private placement of 4,711,126 units at a price of \$0.80 per unit for gross proceeds of \$3,768,901. Each unit is comprised of one common share and one-half common share purchase warrant in the Company. Each whole common share purchase warrant will entitle the holder to purchase one common share in the Company at a price of \$1.10 for a 24-month period following the closing of the private placement or, should the 20-day volume weighted average price of Opsens common shares trade on the TSX Venture Exchange at or above \$1.50 during this same 24-month period, Opsens may accelerate the expiration date of the share purchase warrants by giving prior written notice to the warrant holders within 10 working days immediately following the date on which the triggering event occurs. The share purchase warrants will then expire 30 calendar days after written notice of such an event is received or deemed received by the warrant holders.

Opsens has paid to the agents a cash commission equal to \$263,823 and issued warrants to brokers entitling them to purchase 329,779 common shares in Opsens. The issued broker warrants will have an exercise price per common share equal to the issue price for a period of 24 months from the closing of the private placement. The securities issued as part of the offering were subject to a mandatory four-month restricted period expiring on August 9, 2008.

The net proceeds of the Private placement will be used for acquisitions, marketing and general working capital purposes. The funding obtained will provide Opsens with cash resources to expand its sales and marketing activities and finalize the three main product development partnerships, which should provide long-term recurring revenues to the Company.

Warrants exercised

For the fiscal year ended August 31, 2008, 1,483,611 warrants entitling their holders to acquire one common share in the Company at an average price of \$0.56 per share were exercised for a total amount of \$834,111. The book value of the exercised warrants was transferred to share capital in the amount of \$207,642.

As at the date of this Management Discussion and Analysis, the following components of shareholders' equity are outstanding:

Common shares	40,481,677
Stock options	2,442,500
Warrants	2,796,453
<hr/>	
Securities on a fully diluted basis	45,720,630

On October 3, 2008, 50,000 warrants entitling its holder to acquire one common share of the Company at a price of \$0.40 per share were exercised for an amount of \$20,000. The book value of the exercised warrants was transferred to Share Capital in the amount of \$8,000.

After year end, 393,000 and 4,865,000 warrants entitling its holder to acquire one common share of the Company at a price of \$0.40 and \$0.60 per share respectively expired.

In addition, the Company granted to some employees a total of 210,000 stock options with an average exercise price of \$0.48 per share and cancelled 10,000 stock options with an exercise price of \$0.87 per share.

Investing activities cash flow

Opsens acquired various fixed assets for \$315,000 during the fiscal year ended August 31, 2008, compared to \$142,000 for fiscal year 2007. These acquisitions were made primarily to gain access to high-tech R&D and production equipment. Also, investments were made in order to optimize the recently acquired installations in Edmonton.

As for intangible assets, Opsens invested \$38,000 and \$74,000 for fiscal years 2008 and 2007 respectively. These investments involved patent protection for the Company's inventions.

Cash and cash equivalents

As at August 31, 2008, the Company had cash and cash equivalents of \$3,743,000, compared to \$1,839,000 as at August 31, 2007. Of this amount as at August 31, 2008, \$3,595,000 was invested in highly liquid, safe investments. The Company also has an available line of credit in the amount of \$200,000. This line of credit incurs interest at prime +2%. The restrictive clauses of the Company's financial institution are respected.

Financial position

As at August 31, 2008, Opsens had working capital of \$4,691,000, compared to working capital of \$2,002,000 as at August 31, 2007. Based on the private placement completed on April 8, 2008, the exercised warrants, its cash and cash-equivalents, its working capital, and its order backlog, Opsens has the financial resources necessary to maintain short-term operations, honour its commitments, and support its anticipated growth and development activities. From a medium-term perspective, Opsens may need to raise additional financing by issuing equity securities and debts. In the long term, there is uncertainty about obtaining additional financing, given the risks and uncertainties identified in the *Risks and uncertainties* section. During the coming quarters, fluctuation in cash assets will depend particularly on the rate of revenue growth.

For the next twelve-month period, the widespread sales growth should require the Company to make an additional investment of a few hundred thousand dollars in accounts receivable and inventory.

Commitments

The Company rents offices in Quebec under an operating lease expiring on January 31, 2014. This agreement is renewable for an additional five-year period. Future rent, without considering the escalation clause, will amount to \$640,604.

Opsens Solutions rents offices in Alberta under a letter of agreement. A lease should be signed during the next quarter in order to finalize a verbal commitment. In the event that the lease is not signed, the company was obligated to pay the monthly lease payments until September 30, 2008. As a result, future lease payments will amount to \$4,478 as of August 31, 2008.

Opsens Solutions rents a vehicle under an operating lease expiring in November 2010. Future rent payments will amount to \$18,945.

The Company is committed to purchasing equipment in the amount of \$62,885.

Future payments for the lease and other commitments, totalizing \$1,068,241, required in each of the next five years are as follows:

	\$
2009	372,239
2010	214,443
2011	184,628
2012	121,023
2013	121,523
Thereafter	54,385

The following table summarizes the Company's minimum contractual commitments related to debt for the future fiscal years ending August 31, 2009, 2010, 2011, 2012, and 2013.

	Obligations – Capital leases			Other debts	Debts and principal portion of capital leases
	Total payments	Imputed interest	Principal payments		
2009	\$7,000	\$2,000	\$5,000	\$218,000	\$223,000
2010	\$7,000	\$1,000	\$6,000	\$82,000	\$88,000
2011	\$7,000	\$1,000	\$6,000	\$76,000	\$82,000
2012	\$5,000	\$-	\$5,000	\$39,000	\$43,000
2013	\$-	\$-	\$-	\$38,000	\$38,000

According to the terms of the agreement related to the long-term debt of Investissement Québec and its financial institution, the Company is subject to certain restrictive clauses for maintaining minimum financial ratios.

The Company expects to meet its short-term cash needs with its working capital position.

License

According to an exclusive license agreement with a third party, the Company has committed to providing exclusivity for the marketing of some of its products for a defined territory.

Related-party transactions

During the normal course of business, management and professional fees have been incurred from related parties. These transactions have been valued at the exchange amount agreed by the parties. Professional fees were disbursed in exchange for administrative support and management consulting.

	2008	2007
	\$	\$
Management fees paid to a shareholder	-	833
Professional fees to a company controlled by a shareholder and director	30,000	35,000
	<u>30,000</u>	<u>35,833</u>

Financial instruments

Credit risk

The Company grants credit to its customers in the normal course of business. Evaluations of all of its accounts receivable are performed on an ongoing basis, and an allowance for bad debt is recorded when certain accounts are deemed uncollectible.

Interest rate and cash flow risk

The Company is exposed to interest rate fluctuations on certain long-term debts with variable interest rates. The Company does not actively manage this risk.

Foreign exchange risk

The Company makes some sales and partnership revenue and some purchases of supplies and professional services in US dollars. Therefore, it is exposed to foreign currency fluctuations. The Company does not actively manage this risk. The Company expects that its weighting of Canadian sales will increase simultaneously with sales in the oil and gas sector, which will ease the fluctuation of foreign exchanges on sales in a weighted manner.

Fair value

The fair value of cash and cash equivalents, accounts receivable, income tax credits receivable, and accounts payable and accrued expenses is approximately their carrying value because of their short time to maturity. The fair value of long-term debt is based on the discounted value of future cash flows under the current financial arrangements at the interest rate at which the Company currently expects to be able to obtain loans with similar terms and conditions and maturity dates. The fair value of long-term debt is close to its carrying value because of current market rates.

STRATEGIC ACQUISITIONS AND NEW PROJECT DEVELOPMENT

In its business plan, Opsens has identified some acquisition targets for growth. In order to maximize value creation for our shareholders, and based on the opportunities, Opsens may make strategic acquisitions during the next fiscal year. Opsens remains open to any business opportunities that could occur at any time.

On December 11, 2007, the Company acquired all of the outstanding shares of Inflo Solutions Inc. (“Inflo”), which designs and installs solutions intended for the analysis of reservoirs based on optical and conventional sensors within the oil industry. The purchase price was 1,199,997 Opsens common shares and \$120,000 cash. At the closing, 510,000 shares out of the first 600,000 shares were paid into escrow and will be released over a 48-month period. The balance of the shares and the cash, represented by a series of promissory notes, have also been paid into escrow, to be released or cancelled, as applicable, over a 48-month period ending December 11, 2011, following the achievement or non-achievement of certain performance milestones. The Company has also committed to investing up to \$350,000 into the working capital of Inflo during the 48-month period following the acquisition. As at August 31, 2008, an amount of \$425,000 has been advanced.

On April 8, 2008, a milestone was achieved, releasing a series of promissory notes with a total value of \$60,000. This amount has been booked as goodwill.

On August 31, 2008, the Company renegotiated the agreement made on December 11, 2007. The revised agreement eliminated the possibility of cancelling 499,997 shares against an escrow ending on December 11, 2011.

This acquisition has been accounted for using the purchase method, and the operating results have been included in the company’s consolidated financial statements from the date of acquisition. The purchase price allocation shown below is based on the fair value estimate made by the company:

	Amount
	\$
Assets	
Cash	6,029
Current assets	42,024
Order backlog	20,000
	<u>68,053</u>
Liabilities	
Current liabilities	44,377
Net identifiable assets acquired	23,676
Goodwill	676,574
Purchase price	700,250
Less:	
Cash acquired	6,029
Issuance of shares in connection with the acquisition	525,574
Net cash used for the acquisition	<u>168,647</u>

The value attributed to the order backlog as part of the purchase price allocation has been amortized based on the realization of revenues from present contracts in the order backlog at the time of the acquisition. For the fiscal year

ended August 31, 2008, there was \$20,000 in intangible asset amortization for the order backlog. Goodwill is not deductible for the purposes of income taxes.

The Company now considers the activities of Opsens Solutions as a reportable segments as defined by the CICA Handbook. Opsens Solutions participates in activities related to the oil and gas market. For the year ended August 31, 2008, Opsens Solutions made a positive contribution to revenue growth.

CHANGE IN ACCOUNTING POLICIES

Impact of adopting the new Financial instruments standards

On September 1, 2007, the Company adopted the new accounting standards issued by the Canadian Institute of Chartered Accountants (“CICA”) regarding Financial instruments- Recognition and measurement (Section 3855), Financial Instruments – Disclosure and presentation (Section 3861), Hedges (Section 3865) and Comprehensive Income (section 1530). Information released prior to September 1, 2007 was not restated.

On September 1, 2007, the Company made the following adjustments in order to conform to the new accounting standards:

	Amount
	\$
Decrease	
Balance Sheet	
Assets	
Deferred financing costs	4,336
Liabilities	
Long-term debt	78,023
Statement of deficit	
Change in accounting policies	73,687

Financial Instruments – Recognition and measurement

Short-term investments

Short-term investments are classified as financial instruments “held for trading”. As such, these financial instruments are recorded at their fair values. Changes in the fair value of held for trading instruments are recorded as investment income and disclosed as financial income in the statement of loss.

The fair value of financial instruments represents the amount at which the financial instruments could be traded knowingly and voluntarily between the parties involved. The fair value is based on market prices (buyer-seller prices) in an active market. If this is not the case, the fair value is based on market prices prevailing for instruments with similar risk profiles or characteristics or on internal or external valuation models that use observable market data.

Derivative financial instruments

Derivative financial instruments must be recorded at fair value unless they are specifically designated in an effective hedging relationship, and the change in fair value will be recorded directly in net earnings.

Long-term debt

The long-term debt is classified as “other liabilities” and is recorded at amortized cost.

Transaction fees related to “other liabilities” are capitalized and presented against long-term debt. They are amortized using the effective interest rate and are recorded in the statement of loss.

Other comprehensive income (loss)

According to the new accounting standards, the Company must present a comprehensive income statement. Since the Company has classified all of its financial instruments as financial instruments “held for trading”, except for the long-term debt which is classified as “other liabilities”, there is no element to be disclosed distinctively in other comprehensive income. Consequently, the net earnings (net loss) also represents the results of the comprehensive income (loss).

SIGNIFICANT ACCOUNTING PRINCIPLES

The financial statements have been prepared in accordance with Canadian generally accepted accounting principles (“GAAP”) and include the following policies:

Principles of consolidation

The consolidated financial statements include the accounts of the Company and those of its wholly-owned subsidiary Opsens Solutions Inc. since its acquisition.

Cash and cash equivalents

Cash and cash equivalents include cash and short-term investments redeemable anytime or with a maturity of three months or less beginning on the acquisition date.

Inventories

Raw materials are valued at the lower of cost and replacement cost, and finished goods are valued at the lower of cost and the net realizable value. Cost is determined using the moving average method.

Property, plant and equipment and intangible assets

Property, plant and equipment and intangible assets with finite lives are recorded at their acquisition cost. Amortization is provided using the declining balance method based on their useful lives, except for patents, which are amortized using the straight-line method, at the following annual rates:

Property, plant and equipment and intangible assets

Office furniture and equipment	20%
Production equipment	20%
Automotive equipment	30%
Research and development equipment	20%
Research and development computer equipment	30%
Computer equipment	30%
Leasehold improvements	Lease Term

Intangible assets with limited lives

Patents	Term of underlying patent, 5 to 20 years
Software	30%

Service contracts are intangible assets with definite useful life which were accounted for at cost. Amortization was based on the fair value of the contracts on the total value of the contracts portfolio acquired. The service contracts were fully amortized during the year.

Intangible assets with indefinite lives are recorded at cost and are tested for impairment annually or more frequently if events of changes in circumstances indicate a potential impairment in value. The excess of the carrying value over the fair value is recorded in loss.

Impairment of long-lived assets

Long-lived assets held are reviewed annually or more frequently when events or changes in circumstances cause its carrying value to exceed the total undiscounted cash flows expected from its use and eventual disposition. The impairment loss is calculated by deducting the fair value of the asset from its carrying value.

Deferred financing costs

Deferred financing costs comprise legal expenses and expenses incurred for the issuance of long-term debt and expenses incurred to complete the qualifying transaction and the related placement. Until August 31, 2007, they were amortized using the straight-line method over the term of the corresponding debt. Since September 1st, 2007, the amounts paid are amortized using and presented against corresponding debt (Note 2). Expenses related to the qualifying transaction are applied against shareholders' equity.

Government assistance and income tax credits for research and development

Government grants are recorded when there is reasonable assurance that the Company has complied with and will continue to comply with all the conditions of the grant. Non-repayable grants or contributions related to operating expenses are included in the statement of loss when the related expenses are incurred. Grants related to capital expenditures are netted against the related assets when acquired.

The Company is also eligible for income tax credits for scientific research and experimental development (SR&ED) awarded by the federal and provincial governments. The portion of SR&ED credits immediately receivable is accounted for in the year during which the related costs or capital expenses are incurred. The portion of SR&ED credits not immediately receivable is accounted for in the year during which these costs or expenses are incurred, provided the Company has reasonable assurance that these credits will be recovered.

Income tax credits are applied against expenses or related assets. Recorded income tax credits are based on management's estimates of amounts expected to be recovered and are subject to an audit by the taxation authorities.

Loss per share

Loss per share is determined using the weighted average number of outstanding shares during the period. The Company uses the treasury stock method to calculate the diluting effect of share purchase options and warrants. Reconciliations of the numerators and the denominators used in the calculation of the basic and diluted loss are disclosed in accordance with the GAAP.

Stock-based compensation and other stock-based payments

The Company uses the fair value method to assess the fair value of stock options or warrants as at their date of allocation. The fair value is determined using the Black-Scholes option pricing model and is amortized to earnings over the vesting period with an offset to contributed surplus. When stock options or warrants are exercised, the corresponding contributed surplus and the proceeds received by the Company are credited to share capital.

Income taxes

The Company accounts for income taxes using the tax liability method. Under this method, future income tax assets and liabilities are recognized for deductible or taxable temporary differences between the carrying value and the tax value of the assets and liabilities based on the enacted or substantially enacted tax rates expected to apply to the year in which the differences are expected to reverse.

The Company establishes a valuation allowance against future income tax assets if, based on available information, it is more likely than not that some or all the future income tax assets will not be realized.

Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate prevailing at the balance sheet date while non-monetary items are translated at the historical rate. Revenues and expenses denominated in foreign currencies are recorded at the average rate of exchange prevailing during the period, except for depreciation and amortization, which is translated at the historical rate. Foreign exchange gains or losses are included in expenses for the year.

Goodwill

Goodwill representing the excess of purchase price over fair value of the net identifiable assets of acquired businesses is tested for impairment annually or more frequently when an event or circumstance occurs that indicates that goodwill might be impaired. When the carrying amount exceeds the fair value, an impairment loss is recognized in the statement of earnings in an amount equal to the excess.

Revenue recognition and work in progress

Revenues related to product sales are recognized when convincing evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collection is reasonably guaranteed.

Sensor installation services, contract revenues earned over a long period, and partnership revenues are recorded using the percentage of completion method. Therefore, these revenues are recognized proportionately with the degree of completion of the work. The Company uses the efforts expended method to calculate the degree of completion of work based on the number of hours incurred as at the balance sheet date compared to the estimated total number of hours. Work in progress is valued by taking into consideration the number of hours worked but not yet invoiced and the payments received. Losses are recorded as soon as they become apparent.

Financial instruments

Short-term investments are classified as financial instruments “held for trading”. As such, these financial instruments are recorded at their fair values. Changes in the fair value of held for trading instruments are recorded as investment income and disclosed as financial expenses in the income statement.

The long-term debt is classified as “other liabilities” and is recorded at amortized cost.

Transaction fees related to “other liabilities” are capitalized and presented against long-term debt. They are amortized using the effective interest rate and are recorded in the income statement.

Use of estimates

The presentation of financial statements in accordance with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The main accounting estimates relate to the income tax credit receivable, the provision for warranty and the assumptions used in the determination of the fair value of the stock options and warrants. Actual results could differ from those estimates.

Future accounting changes

The CICA has issued new accounting standards:

Section 3031, Inventories. This Section provides guidance on the determination of cost and its subsequent recognition as an expense, including any write-down to net realizable value. It also provides guidance on the cost formulas that are used to assign costs to inventories. Management of the Company is a review of the new standard and does not expect the adoption of this standard will have a significant impact on the Company's consolidated financial statements.

Section 3862, Financial Instruments – Disclosures. This section describes the required disclosures related to the significance of financial instruments on the Company's financial position and performance and the nature and extent of risks arising for financial instruments to which the Company is exposed and how the Company manages those risks. This Section complements the principles of recognition, measurement, and presentation of financial instruments of Section 3855, Financial Instruments – Recognition and Measurement, Section 3863, Financial Instruments – Presentation and Section 3865, Hedges. The Company's management does not expect the adoption of this standard will have an impact on the consolidated financial statements as the standard relates to note disclosure.

Section 3863, Financial Instruments – Presentation. This section establishes standards for presentation of financial instruments and non-financial derivatives. It replaces standards of Section 3861, Financial Instruments – Disclosure and Presentation. The Company does not expect the adoption of this standard will have an impact on the consolidated financial statements as the standard relates to note disclosure.

Section 1535, Capital Disclosures. This section establishes standards for disclosing information about an entity's capital and how it is managed to enable users of financial statements to evaluate the entity's objectives, policies and procedures for managing capital. The Company does not expect the adoption of this standard will have an impact on the consolidated financial statements as the standard relates to note disclosure.

The above standards will be effective for the Company as of September 1, 2008.

e) Section 3064, Goodwill and intangible assets, replacing Section 3062, Goodwill and other intangible assets and Section 3450, Research and development costs. The new section will be applicable to financial statements relating to fiscal years beginning on or after October 1, 2008. Accordingly, the Company will adopt the new standards for its fiscal year beginning September 1, 2009. It establishes standards for the recognition, measurement, presentation and disclosure of goodwill subsequent to its initial recognition and of intangible assets by profit-oriented enterprises. Standards concerning goodwill are unchanged from the standards included in the previous Section 3062. The Company does not expect that the adoption of this new Section will have a material impact on its consolidated financial statements.

International Financial Reporting Standards

The Accounting Standards Board of Canada has announced that accounting standards in Canada, as used by public companies, will converge to International Financial Reporting Standards ("IFRS") over a transition period that is expected to be complete by 2011. On February 13, 2008, the CICA confirmed 2011 as the official changeover date from current Canadian GAAP to IFRS. The Company will convert to these new standards according to the timetable set with these new rules.

The Company has not begun to assess the future impact of these new standards on its consolidated financial statements.

RISK FACTORS AND UNCERTAINTIES

Opsens operates in an industry that is subject to various risks and uncertainties. The Company's business, financial position, and operating results could be impacted negatively by these risks and uncertainties. The risks and uncertainties listed below are not the only risks and uncertainties that could impact the Company.

Capital requirements

Additional financing may be required for operating and investment activities. There is no guarantee that additional capital would be available for situations that would be acceptable for Opsens and favourable for its growth.

Revenues

Opsens draws most of its revenue from the sale of readout devices and fiber optic sensors. The company feels that the revenue from these products will continue to represent a significant share of Opsens' revenue for the foreseeable future. Consequently, Opsens is particularly vulnerable to fluctuations in the demand for its products. Therefore, if demand for Opsens products decreases significantly, the company and the operating results could be unfavourably affected.

Labour and key personnel

Opsens depends on the services of its engineers, technical employees, and key management personnel. The loss of one of these people could have a significant unfavourable impact on the company, its operating results, and its financial position. The success of Opsens is largely dependent upon its ability to identify, hire, train, motivate, and retain highly skilled management employees, engineers, technical employees, and sales and marketing personnel. Competition for its employees can be intense, and Opsens can only ensure that it will be able to bring in and retain highly skilled technical and management personnel in the future. Its ability to bring in and retain management and technical personnel and the necessary sales and marketing employees could have an unfavourable impact on its growth and future profitability. Opsens may be obligated to increase the compensation paid to current or new employees, which could substantially increase operating expenses.

Growth management and market development

There is no guarantee that Opsens can develop its market significantly, thus affecting its profitability. Opsens' expected rapid growth may create significant pressure on management, operations, and technical resources. Opsens foresees increased operating and personnel expenses in the future. In order to manage its growth, Opsens may need to increase the size of its technical and operational staff and manage its personnel while maintaining many effective relationships with third parties. There is no guarantee that Opsens will be able to manage its business growth. The inability of Opsens to establish consistent management systems, add economic resources, or manage its expansion adequately will have a significant, unforeseeable effect on its activities and operating results.

Pricing policies

The competitive market in which Opsens operates could force it to reduce its prices. If its competitors offer large discounts on certain products and services in order to gain market share or sell products and services, Opsens may need to lower its prices and offer other favourable terms in order to compete successfully. Such changes could reduce profit margins and have an unfavourable impact on its operating results. Some of Opsens' competitors could offer products and services that compete with theirs for promotional purposes or as part of a long-term pricing strategy or offer price guarantees or product implementation. With time, these practices could limit the prices that Opsens may charge for its products and services. If Opsens cannot offset these price reductions with a corresponding increase in sales or decreased expenses, the decreased revenues from products and services could unfavourably affect its profit margins and operating results.

Product failures and mistakes

Opsens products are complex and therefore may contain failures and mistakes that could be detected at any time in a product's life cycle. Failures and mistakes in its products could have a significant unfavourable impact on its reputation, open it up to significant costs, delay product launch dates, and harm its ability to sell its products in the future. The costs of correcting a failure or mistake in one of these products could be significant and could negatively affect its operating margins. Although Opsens expects to continue to test products to detect failures and mistakes and

to work with its customers through its support and maintenance services in order to find and correct failures and mistakes, they could appear in its products in the future.

Warranties, recalls, and legal proceedings

Opsens is exposed to warranty expenses, product recalls, and other claims, particularly if the products prove to be defective, which would harm business development and the Company's reputation.

Intellectual property and exclusive rights

In order to protect its intellectual property rights, Opsens relies on a combination of laws related to patents and trademarks, trade secrets, confidentiality procedures, and contractual provisions. Despite Opsens' best efforts to protect its intellectual property rights, unauthorized individuals may attempt to copy certain aspects of Opsens products or obtain information that Opsens considers to be its property. The monitoring of the unauthorized use of exclusive technologies, if applicable, may prove difficult, time-consuming, and expensive. In addition, the laws of certain countries in which Opsens products will be sold do not protect their products and their related intellectual property rights in the same way as the laws of Canada and the United States. There is no certainty that Opsens will successfully protect its intellectual property rights, which could unfavourably affect it. Patents applications, claims, PCTs, and Continuations in Part files by Opsens could be incomplete, invalid, circumvented, or deemed not applicable. Legal proceedings could prove necessary to carry out patent applications, claims, PCTs, and Continuations in Part. These cases could lead to considerable expenses without any guarantee of success. Despite Opsens' best efforts to ensure its right to market its products on its target markets, competitor patents could impede the sales potential of certain products.

Competition and technological obsolescence

Competitors and new companies could launch new products. In order to remain on the cutting edge of technology, Opsens may need to launch a new generation of fiber optic sensors and develop its related products and services. Whether it is competition from development companies and/or marketing of fiber optic sensors or a merger or acquisition of existing companies, competition within certain fiber optic sensor industry sectors offering solutions similar to what Opsens offers is vigorous and could increase. Some of Opsens' competitors have significantly greater financial, technical, distribution, and marketing resources than Opsens. Technological progress and product development could make Opsens products obsolete or reduce their value.

Currency exchange rate

Since Opsens makes most of its sales in US dollars, while a large part of its operating expenses are incurred in Canadian dollars, exchange rate fluctuations between the two currencies may have an unfavourable impact on its activities, financial position, and operating results. Based on outlooks and its expected penetration in the oil and gas market, the weighting of Canadian sales should increase during the coming fiscal years and, consequently, reduce Opsens' currency exchange risk.

Restrictive clauses

The Company has restrictive clauses regarding indebtedness and working capital in the agreement with its financial institution. If these restrictive clauses are not respected, Opsens may need to allocate a portion of its working capital to repaying the LFPEC loan, valued at \$77,132 as at August 31, 2008.

OTHER INFORMATION

Updated information on the Company can be found on the SEDAR Web site at <http://www.sedar.com>.

On behalf of management,
Chief Financial Officer and Secretary

(s) Louis Laflamme

November 26, 2008

Auditors' Report

To the Shareholders of
Opsens Inc.

We have audited the consolidated balance sheets of Opsens Inc. as at August 31, 2008 and 2007 and the consolidated statements of loss and comprehensive loss, deficit and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at August 31, 2008 and 2007 and the results of its operations and its cash flows for the years then ended in accordance with Canadian generally accepted accounting principles.

*Samson Bélair
Deloitte & Touche s.e.n.c.r.l.*

Chartered Accountants

October 10, 2008

Opsens Inc.

Consolidated Statements of Loss and Comprehensive Loss Years ended August 31, 2008 and 2007

	2008	2007
	\$	\$
Revenues		
Sales	2,844,239	813,108
Cost of sales	1,432,385	638,898
Gross margin	1,411,854	174,210
Expenses (Revenues)		
Administrative	984,316	622,991
Marketing	730,309	825,392
Research and development	698,957	590,772
Stock option-based compensation (Note 12b)	252,576	345,368
Amortization of property, plant and equipment	100,257	71,723
Amortization of intangible assets	40,340	17,696
Write-off of intangible assets	-	12,209
Amortization of deferred financing fees	-	9,938
Financial income	(58,213)	(8,861)
	2,748,542	2,487,228
Loss before income taxes	(1,336,688)	(2,313,018)
Income taxes (Note 18)	-	-
Net loss and comprehensive loss	(1,336,688)	(2,313,018)
Net loss per share (Note 13)		
Basic	(0.04)	(0.08)
Diluted	(0.04)	(0.08)

The accompanying notes are an integral part of the consolidated financial statements.

Additional information on the Statements of Loss is presented in Note 22.

Opsens Inc.

Consolidated Statements of Deficit

Years ended August 31, 2008 and 2007

	2008	2007
	\$	\$
Balance at beginning	4,587,145	1,757,494
Changes in accounting policies (Note 2)	(73,687)	-
Net loss	1,336,688	2,313,018
Issuance expenses on equity component	532,340	516,633
Balance at end	6,382,486	4,587,145

The accompanying notes are an integral part of the consolidated financial statements.

Opsens Inc.

Consolidated Balance Sheets

August 31, 2008 and 2007

	2008	2007
	\$	\$
Assets		
Current		
Cash and cash equivalents (Note 14)	3,742,520	1,839,379
Accounts receivable (Note 5)	743,951	120,697
Income tax credits receivable (Note 18)	183,950	177,355
Work in progress	237,551	-
Inventories (Note 6)	453,271	372,650
Prepaid expenses	100,454	32,593
	5,461,697	2,542,674
Property, plant and equipment (Note 7)	554,180	339,293
Intangible assets (Note 8)	159,768	142,444
Deferred financing costs	-	4,336
Goodwill	676,574	-
	6,852,219	3,028,747
Liabilities		
Current		
Accounts payable and accrued liabilities (Notes 10 and 16)	547,204	320,960
Deferred revenue	-	20,000
Current portion of long-term debt (Note 11)	223,265	200,315
	770,469	541,275
Long-term debt (Note 11)	252,380	498,927
	1,022,849	1,040,202
Shareholders' equity		
Share capital (Note 12a)	10,257,259	5,332,483
Stock-options (Note 12b)	554,528	408,701
Warrants (Note 12c)	1,400,069	834,506
Deficit	(6,382,486)	(4,587,145)
	5,829,370	1,988,545
	6,852,219	3,028,747

The accompanying notes are an integral part of the financial statements.

References:

Commitments (Note 15)
Contractual guarantees (Note 16)
Subsequent events (Note 24)

Approved by the Board

Signed [Mario Jacob] Director

Signed [Pierre Carrier] Director

Opsens Inc.

Consolidated Statements of Cash Flows Years ended August 31, 2008 and 2007

	2008	2007
	\$	\$
Operating activities		
Net loss	(1,336,688)	(2,313,018)
Adjustments for:		
Amortization of property, plant and equipment	100,257	71,723
Amortization of intangible assets	40,340	17,696
Write-off of intangible assets	-	12,209
Amortization of deferred financing costs	-	9,938
Premium payable to <i>Canada Economic Development</i>	16,799	10,908
Premium payable to <i>Investissement Québec</i>	8,520	8,520
Stock option-based compensation	252,576	345,368
Changes in non-cash operating working capital items (Note 14)	(811,991)	185,878
	(1,730,187)	(1,650,778)
Investing activities		
Acquisition of property, plant and equipment	(315,144)	(142,300)
Disposal of property, plant and equipment	-	20
Acquisition of intangible assets	(37,664)	(73,661)
Cash and cash equivalents paid in business combination (Note 4)	(168,647)	-
	(521,455)	(215,941)
Financing activities		
Increase in deferred financing costs	-	(48,164)
Increase in long-term debt	72,966	106,900
Reimbursement of demand loan	-	(204,824)
Reimbursement of long-term debt	(243,859)	(183,615)
Issuance of equity component	4,741,011	3,495,000
Issuance of equity component expenses	(415,335)	(341,335)
Cash and cash equivalents acquired in the qualifying transaction (Note 1)	-	558,716
	4,154,783	3,382,678
Increase in cash and cash equivalents	1,903,141	1,515,959
Cash and cash equivalents at beginning	1,839,379	323,420
Cash and cash equivalents at end	3,742,520	1,839,379

The accompanying notes are an integral part of the consolidated financial statements.

Additional information is presented in Note 14.

Opsens inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

1. Description of business

During the year ended August 31, 2007, the Company, formerly known as DCB Capital Inc., changed its name to Opsens Inc. following the completion of a qualifying transaction.

The Company issued from the qualifying transaction specializes in developing and manufacturing technical and scientific instruments.

This transaction constitutes a qualifying transaction as per Policy 2.4 of the TSX Venture Exchange Corporate Finance Manual. The transaction was realized by means of an acquisition followed by a merger carried out on October 3, 2006.

As part of the qualifying transaction and according to the rules of the TSX Venture Exchange, DCB Capital Inc. issued 20,000,000 of its common shares to shareholders holding Opsens Inc. class A shares in exchange for the acquisition of all Opsens Inc. class A shares, at the price of \$0.40 per common share.

For accounting and disclosure purposes, this type of share exchange constitutes a reverse takeover, under which Opsens Inc. is deemed to have issued shares in consideration for the net assets of DCB Capital Inc. Consequently, the control of DCB Capital Inc. was transferred to the shareholders of Opsens Inc.

In compliance with EIC-10 of the CICA Handbook, this reverse takeover constitutes an equity transaction rather than a business combination. Consequently, no goodwill or intangible assets are accounted for, and the company's financial statements present the continuance of Opsens Inc.

Under the terms of the qualifying transaction, the net value of the acquired assets of DCB Capital Inc. is as follows:

	October 3, 2006
	\$
Cash and cash equivalents (\$558,716) and other current assets	576,735
Demand loan receivable from Opsens Inc.	250,000
Liabilities	(18,432)
Net value	808,303

The consideration issued as part of this business combination is allocated as follows:

	October 3, 2006
	\$
20,000,000 common shares	744,970
333,333 stock options revalued at fair value as of October 3, 2006	63,333
	808,303

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

2. Changes in accounting policies

Impact of adopting the new Financial instruments standards

On September 1, 2007, the Company adopted the new accounting standards issued by the Canadian Institute of Chartered Accountants ("CICA") regarding Financial instruments- Recognition and measurement (Section 3855), Financial Instruments – Disclosure and presentation (Section 3861), Hedges (Section 3865) and Comprehensive Income (section 1530). Information released prior to September 1, 2007 was not restated.

On September 1, 2007, the Company made the following adjustments in order to conform to the new accounting standards:

	Amount
	\$
<i>Decrease</i>	
Balance Sheet	
Assets	
Deferred financing costs	4,336
Liabilities	
Long-term debt	78,023
Statement of deficit	
Change in accounting policies	73,687

Financial Instruments – Recognition and measurement

Short-term investments

Short-term investments are classified as financial instruments "held for trading". As such, these financial instruments are recorded at their fair values. Changes in the fair value of held for trading instruments are recorded as investment income and disclosed as financial income in the statement of loss.

The fair value of financial instruments represents the amount at which the financial instruments could be traded knowingly and voluntarily between the parties involved. The fair value is based on market prices (buyer-seller prices) in an active market. If this is not the case, the fair value is based on market prices prevailing for instruments with similar risk profiles or characteristics or on internal or external valuation models that use observable market data.

Derivative financial instruments

Derivative financial instruments must be recorded at fair value unless they are specifically designated in an effective hedging relationship, and the change in fair value will be recorded directly in net earnings.

Long-term debt

The long-term debt is classified as "other liabilities" and is recorded at amortized cost.

Transaction fees related to "other liabilities" are capitalized and presented against long-term debt. They are amortized using the effective interest rate and are recorded in the statement of loss.

Other comprehensive income (loss)

According to the new accounting standards, the Company must present a comprehensive income statement. Since the Company has classified all of its financial instruments as financial instruments "held for trading", except for the long-term debt which is classified as "other liabilities", there is no element to be disclosed distinctively in other comprehensive income. Consequently, the net earnings (net loss) also represents the results of the comprehensive income (loss).

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

3. Accounting policies

The financial statements have been prepared in accordance with Canadian generally accepted accounting principles ("GAAP") and include the following policies:

Principles of consolidation

The consolidated financial statements include the accounts of the Company and those of its wholly-owned subsidiary Opsens Solutions Inc. since its acquisition.

Cash and cash equivalents

Cash and cash equivalents include cash and short-term investments redeemable anytime or with a maturity of three months or less beginning on the acquisition date.

Inventories

Raw materials are valued at the lower of cost and replacement cost, and finished goods are valued at the lower of cost and the net realizable value. Cost is determined using the moving average method.

Property, plant and equipment and intangible assets

Property, plant and equipment and intangible assets with finite lives are recorded at their acquisition cost. Amortization is provided using the declining balance method based on their useful lives, except for patents, which are amortized using the straight-line method, at the following annual rates:

Property, plant and equipment and intangible assets

Office furniture and equipment	20%
Production equipment	20%
Automotive equipment	30%
Research and development equipment	20%
Research and development computer equipment	30%
Computer equipment	30%
Leasehold improvements	Lease Term

Intangible assets with limited lives

Patents	Term of underlying patent, 5 to 20 years
Software	30%

Service contracts are intangible assets with definite useful life which were accounted for at cost. Amortization was based on the fair value of the contracts on the total value of the contracts portfolio acquired. The service contracts were fully amortized during the year.

Intangible assets with indefinite lives

Intangible assets with indefinite lives are recorded at cost and are tested for impairment annually or more frequently if events of changes in circumstances indicate a potential impairment in value. The excess of the carrying value over the fair value is recorded in loss.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

3. Accounting policies (continued)

Impairment of long-lived assets

Long-lived assets held are reviewed annually or more frequently when events or changes in circumstances cause its carrying value to exceed the total undiscounted cash flows expected from its use and eventual disposition. The impairment loss is calculated by deducting the fair value of the asset from its carrying value.

Deferred financing costs

Deferred financing costs comprise legal expenses and expenses incurred for the issuance of long-term debt and expenses incurred to complete the qualifying transaction and the related placement. Until August 31, 2007, they were amortized using the straight-line method over the term of the corresponding debt. Since September 1st, 2007, the amounts paid are amortized using and presented against corresponding debt (Note 2). Expenses related to the qualifying transaction are applied against shareholders' equity.

Government assistance and income tax credits for research and development

Government grants are recorded when there is reasonable assurance that the Company has complied with and will continue to comply with all the conditions of the grant. Non-repayable grants or contributions related to operating expenses are included in the statement of loss when the related expenses are incurred. Grants related to capital expenditures are netted against the related assets when acquired.

The Company is also eligible for income tax credits for scientific research and experimental development (SR&ED) awarded by the federal and provincial governments. The portion of SR&ED credits immediately receivable is accounted for in the year during which the related costs or capital expenses are incurred. The portion of SR&ED credits not immediately receivable is accounted for in the year during which these costs or expenses are incurred, provided the Company has reasonable assurance that these credits will be recovered.

Income tax credits are applied against expenses or related assets. Recorded income tax credits are based on management's estimates of amounts expected to be recovered and are subject to an audit by the taxation authorities.

Loss per share

Loss per share is determined using the weighted average number of outstanding shares during the period. The Company uses the treasury stock method to calculate the diluting effect of share purchase options and warrants. Reconciliations of the numerators and the denominators used in the calculation of the basic and diluted loss are disclosed in accordance with the GAAP.

Stock-based compensation and other stock-based payments

The Company uses the fair value method to assess the fair value of stock options or warrants as at their date of allocation. The fair value is determined using the Black-Scholes option pricing model and is amortized to earnings over the vesting period with an offset to contributed surplus. When stock options or warrants are exercised, the corresponding contributed surplus and the proceeds received by the Company are credited to share capital.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

3. Accounting policies (continued)

Income taxes

The Company accounts for income taxes using the tax liability method. Under this method, future income tax assets and liabilities are recognized for deductible or taxable temporary differences between the carrying value and the tax value of the assets and liabilities based on the enacted or substantially enacted tax rates expected to apply to the year in which the differences are expected to reverse.

The Company establishes a valuation allowance against future income tax assets if, based on available information, it is more likely than not that some or all the future income tax assets will not be realized.

Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate prevailing at the balance sheet date while non-monetary items are translated at the historical rate. Revenues and expenses denominated in foreign currencies are recorded at the average rate of exchange prevailing during the period, except for depreciation and amortization, which is translated at the historical rate. Foreign exchange gains or losses are included in expenses for the year.

Goodwill

Goodwill representing the excess of purchase price over fair value of the net identifiable assets of acquired businesses is tested for impairment annually or more frequently when an event or circumstance occurs that indicates that goodwill might be impaired. When the carrying amount exceeds the fair value, an impairment loss is recognized in the statement of earnings in an amount equal to the excess.

Revenue recognition and work in progress

Revenues related to product sales are recognized when convincing evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collection is reasonably guaranteed.

Sensor installation services, contract revenues earned over a long period, and partnership revenues are recorded using the percentage of completion method. Therefore, these revenues are recognized proportionately with the degree of completion of the work. The Company uses the efforts expended method to calculate the degree of completion of work based on the number of hours incurred as at the balance sheet date compared to the estimated total number of hours. Work in progress is valued by taking into consideration the number of hours worked but not yet invoiced and the payments received. Losses are recorded as soon as they become apparent.

Financial instruments

Short-term investments are classified as financial instruments "held for trading". As such, these financial instruments are recorded at their fair values. Changes in the fair value of held for trading instruments are recorded as investment income and disclosed as financial expenses in the income statement.

The long-term debt is classified as "other liabilities" and is recorded at amortized cost.

Transaction fees related to "other liabilities" are capitalized and presented against long-term debt. They are amortized using the effective interest rate and are recorded in the income statement.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

3. Accounting policies (continued)

Use of estimates

The presentation of financial statements in accordance with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The main accounting estimates relate to the income tax credit receivable, the provision for warranty and the assumptions used in the determination of the fair value of the stock options and warrants. Actual results could differ from those estimates.

Future accounting changes

The CICA has issued new accounting standards:

- a) Section 3031, Inventories. This Section provides guidance on the determination of cost and its subsequent recognition as an expense, including any write-down to net realizable value. It also provides guidance on the cost formulas that are used to assign costs to inventories. Management of the Company is a review of the new standard and does not expect the adoption of this standard will have a significant impact on the Company's consolidated financial statements.
- b) Section 3862, Financial Instruments – Disclosures. This section describes the required disclosures related to the significance of financial instruments on the Company's financial position and performance and the nature and extent of risks arising for financial instruments to which the Company is exposed and how the Company manages those risks. This Section complements the principles of recognition, measurement, and presentation of financial instruments of Section 3855, Financial Instruments – Recognition and Measurement, Section 3863, Financial Instruments – Presentation and Section 3865, Hedges. The Company's management does not expect the adoption of this standard will have an impact on the consolidated financial statements as the standard relates to note disclosure.
- c) Section 3863, Financial Instruments – Presentation. This section establishes standards for presentation of financial instruments and non-financial derivatives. It replaces standards of Section 3861, Financial Instruments – Disclosure and Presentation. The Company does not expect the adoption of this standard will have an impact on the consolidated financial statements as the standard relates to note disclosure.
- d) Section 1535, Capital Disclosures. This section establishes standards for disclosing information about an entity's capital and how it is managed to enable users of financial statements to evaluate the entity's objectives, policies and procedures for managing capital. The Company does not expect the adoption of this standard will have an impact on the consolidated financial statements as the standard relates to note disclosure.

The above standards will be effective for the Company as of September 1, 2008.

- e) Section 3064, Goodwill and intangible assets, replacing Section 3062, Goodwill and other intangible assets and Section 3450, Research and development costs. The new section will be applicable to financial statements relating to fiscal years beginning on or after October 1, 2008. Accordingly, the Company will adopt the new standards for its fiscal year beginning September 1, 2009. It establishes standards for the recognition, measurement, presentation and disclosure of goodwill subsequent to its initial recognition and of intangible assets by profit-oriented enterprises. Standards concerning goodwill are unchanged from the standards included in the previous Section 3062. The Company does not expect that the adoption of this new Section will have a material impact on its consolidated financial statements.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

3. Accounting policies (continued)

Future accounting changes (continued)

International Financial Reporting Standards

The Accounting Standards Board of Canada has announced that accounting standards in Canada, as used by public companies, will converge to International Financial Reporting Standards ("IFRS") over a transition period that is expected to be complete by 2011. On February 13, 2008, the CICA confirmed 2011 as the official changeover date from current Canadian GAAP to IFRS. The Company will convert to these new standards according to the timetable set with these new rules.

The Company has not begun to assess the future impact of these new standards on its consolidated financial statements.

4. Business acquisition

On December 11, 2007, the Company concluded the acquisition of all outstanding shares of Inflo Solutions Inc. ("Inflo"), a company dedicated to the design and installation of reservoir surveillance solutions based on optical and conventional sensors to the oil and gas market. The purchase price is comprised of 1,199,997 Opsens common shares and \$120,000 cash. At the closing, 510,000 shares out of the first 600,000 shares were paid into escrow and will be released over a 48-month period. The balance of the shares and the cash, represented by a series of promissory notes, have also been paid in escrow, to be released or cancelled, as applicable, over a 48-month period ending December 11, 2011, following the achievement or non achievement of certain performance milestones. The Company has also committed to invest up to \$350,000 into the working capital of Inflo during the 48-month period following the acquisition. The shares issued at closing are subject to a statutory 4-month hold period ending on April 12, 2008.

On April 8, 2008, a milestones had been achieved which had effect to release a series of promissory notes for a total value of \$60,000. This amount had been booked as goodwill.

On August 31, 2008, the Company renegotiated the agreement made on December 11, 2007. The revised agreement eliminated the possibility of cancelling 499,997 shares against an escrow ending on December 11, 2011.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

4. Business acquisition (continued)

The acquisition has been accounted for using the purchase method, and the results of operations have been included in the consolidated financial statements of the company from the date of acquisition. The purchase price allocation shown below is based on the fair value estimate made by the company :

	Amount
	\$
Assets	
Cash	6,029
Current assets	42,024
Service contracts	20,000
	<u>68,053</u>
Liabilities	
Current liabilities	44,377
	<u>44,377</u>
Net identifiable assets acquired	23,676
Goodwill*	676,574
	<u>700,250</u>
Purchase price	700,250
Less :	
Cash acquired	6,029
Issuance of shares in connection with the acquisition	525,574
	<u>531,603</u>
Net cash used for the acquisition	<u>168,647</u>

* Goodwill is not deductible for income taxes calculation.

On December 11, 2007, the company Inflo changed its name for Opsens Solutions Inc. ("Opsens Solutions").

5. Accounts receivable

	2008	2007
	\$	\$
Trade	729,406	73,929
Allowance for doubtful accounts	(14,031)	-
Taxes receivable	28,576	33,824
Others	-	12,944
	<u>743,951</u>	<u>120,697</u>

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

6. Inventories

	2008	2007
	\$	\$
Raw materials	380,885	299,007
Finished goods	72,386	73,643
	453,271	372,650

7. Property, plant and equipment

	2008		
	Cost	Accumulated Amortization	Net Book Value
	\$	\$	\$
Office furniture and equipment	52,723	24,666	28,057
Leased office furniture and equipment	12,535	3,225	9,310
Production equipment	88,020	25,018	63,002
Leased Automotive equipment	16,500	2,200	14,300
Research and development equipment, net of income tax credits of \$23,834	582,134	202,577	379,557
Research and development computer equipment, net of income tax credits of \$3,078	24,270	15,649	8,621
Computer equipment	74,298	27,713	46,585
Leasehold improvements	12,905	8,157	4,748
	863,385	309,205	554,180

	2007		
	Cost	Accumulated Amortization	Net Book Value
	\$	\$	\$
Office furniture and equipment	44,942	16,276	28,666
Leased office furniture and equipment	12,535	2,128	10,407
Production equipment	51,267	14,153	37,114
Research and development equipment, net of income tax credits of \$23,834	360,109	145,139	214,970
Research and development computer equipment, net of income tax credits of \$3,078	20,331	12,304	8,027
Computer equipment	52,158	18,182	33,976
Leasehold improvements	6,900	767	6,133
	548,242	208,949	339,293

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

8. Intangible assets

	2008		
	Cost	Accumulated Amortization	Net Book Value
	\$	\$	\$
Indefinite lives			
Trademarks	200	-	200
Limited lives			
Patents	172,036	30,445	141,591
Software, net of income tax credits of \$1,518	41,578	23,601	17,977
	213,814	54,046	159,768
			2007
	Cost	Accumulated Amortization	Net Book Value
	\$	\$	\$
Indefinite lives			
Trademarks	200	-	200
Limited lives			
Patents	139,260	16,772	122,488
Software, net of income tax credits of \$1,518	36,690	16,934	19,756
	176,150	33,706	142,444

Due to the abandonment of a patent application, an impairment loss of \$12,209 was recognized as of August 31, 2007.

9. Authorized line of credit

The Company has an authorized line of credit for a maximum amount of \$200,000, \$50,000 of which is available at all times and which does not take into consideration the margining. When using the line of credit in an amount varying from \$50,000 and \$100,000, the available credit is limited to an amount that is equal to 75% of Canadian accounts receivable and 65% of foreign accounts receivable plus 50% of inventories of raw materials and finished goods. If the amount used exceeds \$100,000, the credit available is limited to an amount equal to 75% of Canadian accounts receivable and 90% of ensured foreign accounts receivable plus 50% of inventories of raw materials and finished goods. This line of credit bears interest at the financial institution's prime rate plus 2% and is repayable on a weekly basis by \$5,000 tranches. It is secured by a first-rank movable hypothec for an amount of \$750,000 on the universality of receivables and inventories. Under the terms and conditions of the credit agreement, the Company is subject to certain covenants with respect to maintaining minimum financial ratios.

The Company also has credit cards for a maximum amount of \$50,000 to finance its current operations. The balance used on these credit cards bears interest at the financial institution's prime rate plus 4%.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

10. Accounts payable and accrued liabilities

	2008	2007
	\$	\$
Suppliers	527,204	304,648
Provision for warranty	20,000	16,312
	547,204	320,960

11. Long-term debt

	2008	2007
	\$	\$
BDC loan of an authorized amount of \$285,000, bearing interest at the Bank's prime rate plus 2.5%, repayable in monthly principal instalments of \$3,690 and a final payment of \$870 in January 2011, secured by a first-rank movable hypothec in the amount of \$285,000 on the universality of the Company's present and future, tangible and intangible property, subordinated only with respect to trade accounts receivable and inventories provided as security for the operating loans or operating lines of credits, and for which the BDC granted a subordinate clause in favour of <i>Investissement Québec</i> for an amount of \$255,750 on the intellectual property, and by joint and several suretyship of certain shareholders for an amount equal to 25% of the outstanding commitment	126,330	170,610
<i>Investissement Québec</i> loan of an authorized amount of \$213,000, bearing interest at the weekly variable rate plus 3%, repayable in monthly principal instalments of \$5,071 and a monthly premium of \$1,014 starting in March 2006, maturing in September 2009, secured by a first-rank movable hypothec in the amount of \$255,750 on the universality of the Company's present and future, tangible and intangible property, subordinated only with respect to trade accounts receivable and inventories provided as security for the operating loans or operating lines of credit, up to a maximum amount of \$213,000	58,417	129,017
Amounts carried forward	184,747	299,627

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

11. Long-term debt (continued)

	2008	2007
	\$	\$
Amounts carried forward	184,747	299,627
Contribution repayable to <i>Canada Economic Development</i> for a maximum amount of \$100,000, repayable by annual royalties equal to 4% of gross annual sales effective September 1, 2004 up to 150% of the contribution paid. The total amount of the contribution should be repaid no later than November 1, 2011. The first repayment is due and payable effective November 1, 2006. Subsequent payments are due annually	-	33,121
Contributions repayable to <i>Canada Economic Development</i> for a maximum amount of \$297,835, repayable in five equal and consecutive annual instalments effective February 1, 2008 for the first contribution and June 11, 2009 for the second	191,203	331,036
Canada Small Business Financing Act loan, for an authorized amount of \$119,340, bearing interest at the financial institution's prime rate plus 2.75% annually, repayable in monthly principal instalments of \$1,423 until May 2009, secured by a first-rank movable hypothec in the amount of \$119,340 on specific property	77,132	25,160
Capital lease, bearing interest at 10.6%, payable in monthly instalments of \$98, including interest and a final payment of \$486 maturing in March 2011	2,964	3,783
Capital lease, bearing interest at 13.5%, payable in monthly instalments of \$140, including interest and a final payment of \$740 maturing in August 2012	5,663	6,515
Capital lease, bearing interest at 13.5%, payable in monthly instalments of \$375, including interest and a final payment of \$1,650 maturing in August 2012	13,936	-
	475,645	699,242
Current portion	223,265	200,315
	252,380	498,927

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

11. Long-term debt (continued)

Principal payments required over the next five years are as follows:

	Obligations – Capital lease			Other debt	Debt and principal portion of capital lease
	Total payments	Imputed interest	Principal payments		
	\$	\$	\$	\$	\$
2009	7,363	2,094	5,269	217,996	223,265
2010	7,363	1,535	5,828	82,440	88,268
2011	7,258	901	6,357	75,932	82,289
2012	5,296	187	5,109	38,479	43,588
2013	-	-	-	38,235	38,235

Under the terms and conditions of the agreement on long-term debt with *Investissement Québec* and its financial institution, the Company is subject to certain covenants with respect to maintaining minimum financial ratios.

12. Share capital, stock-options and warrants

a) Share capital

Authorized, unlimited number

Common shares, voting and participating without par value

Year ended August 31, 2008

Outstanding shares and the changes occurred during the year are as follows:

Issued and fully paid

	Number	Amount
		\$
Balance at beginning of year	32,628,610	5,332,483
Share issuance – Inflo Solutions Inc. (Note 4)	1,199,997	525,574
Share issuance – options exercised	408,333	244,249
Share issuance – warrants exercised i)	1,483,611	1,042,253
Share issuance – Private placement ii)	4,711,126	3,112,700
Balance as at August 31, 2008	40,431,677	10,257,259

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

12. Share capital, stock-options and warrants

a) Common share capital (continued)

i) Warrants exercised

During the year ended August 31, 2008, 1,483,611 warrants entitling their holders to acquire one common share of the Company at an average price of \$0.56 per share were exercised for a total amount of \$834,611. The book value of the exercised warrants was transferred to Share capital for an amount of \$207,642.

ii) Private Placement

On April 8, 2008, the Company realized a private placement of 4,711,126 units at a price of \$0.80 per unit for gross proceeds of \$3,768,901. Each unit is comprised of one common share and one-half common share purchase warrant of the Company. Each warrant will entitle the holder to purchase one common share of the Company at a price of \$1.10 for a period of 24 months following the closing of the Offering, or in the event the 20-day volume weighted average price of the common shares of Opsens trade, on the TSX Venture Exchange, is at or above \$1.50 during this same 24-month period. Then, the warrants must be exercised or will expire 30 calendar days after notice of such event is received or deemed received by the warrant holders. The notice must be given within the 10-working-day period following the event date.

Opsens paid to the Agents a cash commission equal to \$263,823 and issue broker compensation warrants entitling the Agents to purchase 329,779 common shares of Opsens. The Broker Warrants shall be issuable at an exercise price per common share equal to the Offering Price for a period of 24 months from the closing of the Offering. The securities issued pursuant to the Offering will be subject to a 4-month restricted period expiring on August 9, 2008.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

12. Share capital, stock-options and warrants (continued)

a) Common share capital (continued)

Year ended August 31, 2007

Following the transaction described in Note 1 and in accordance with EIC-10, the capital structure appearing is that of DCB Capital Inc. and the dollar amounts presented are that of Opsens Inc.

Outstanding shares and the changes occurred during the year ended August 31, 2007 are as follows:

	Number	Amount \$
Balance as at August 31, 2006		1,082,372
Reclassification of Class A common shares retractable at the option of the shareholder following the cancellation of the retraction right iii)		<u>773,767</u>
	4,346,666	1,856,139
Common shares issued pursuant to the reverse takeover iv)	20,000,000	744,970
Share issuance – Private placement v)	2,600,000	754,000
Share issuance – Private placement vi)	2,937,500	851,875
Share issuance – Private placement vii)	2,444,444	912,499
Share issuance – warrants exercised viii)	<u>300,000</u>	<u>213,000</u>
Balance as at August 31, 2007	<u>32,628,610</u>	<u>5,332,483</u>

iii) Termination of the shareholders' agreement and cancellation of the retraction right

Immediately preceding the share exchange, the agreement between shareholders of Opsens Inc. was terminated and the retraction right of the shares was also cancelled. Consequently, the Class A retractable shares retractable at the option of the shareholder, in the amount of \$773,767, presented in the liabilities of Opsens Inc. as at August 31, 2006 were reclassified in equity.

iv) Qualifying transaction

As part of the qualifying transaction and according to the rules of the TSX Venture Exchange, DCB Capital Inc. issued 20,000,000 of its common shares to shareholders holding Opsens Inc. class A shares in exchange for the acquisition of all Opsens Inc. class A shares, at the price of \$0.40 per common share.

v) Private placement – October 3, 2006

On October 3, 2006, the Company realized a private placement of 2,600,000 units at a price of \$0.40 per unit, for a total of \$1,040,000. Each unit is made up of one common share and one share purchase warrant of the Company. Each purchase warrant entitles its holder to acquire one common share of the Company at a price of \$0.60 per share no later than October 3, 2008. The underlying securities for the units issued as part of this placement are subject to a holding period until February 4, 2007.

vi) Private placement – October 11, 2006

On October 11, 2006, the Company realized a private placement of 2,937,500 units at a price of \$0.40 per unit, for a total of \$1,175,000. Each unit is made up of one common share and one share purchase warrant of the Company. Each purchase warrant entitles its holder to acquire one common share of the Company at a price of \$0.60 per share no later than October 11, 2008. The underlying securities for the units issued as part of this placement are subject to a holding period until February 12, 2007.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

12. Share capital, stock-options and warrants (continued)

a) Common share capital (continued)

vii) Private placement – December 5, 2006

On December 5, 2006, the Company realized a private placement of 2,444,444 units at a price of \$0.45 per unit, for a total of \$1,100,000. Each unit is made up of one common share and a half share purchase warrant of the Company. Each complete warrant entitles its holder to acquire one common share of the Company at a price of \$0.55 per share no later than December 5, 2008. The underlying securities for the units issued as part of this placement are subject to a holding period until April 6, 2007. Pursuant to an underwriting agreement entered into with Desjardins Securities Inc. dated October 3, 2006, the Company paid a lump sum of \$50,000 in fees.

viii) Warrants exercised

During the year ended August 31, 2007, 300,000 warrants entitling their holders to acquire one common share of the Company at a price of \$0.60 per share were exercised for a total amount of \$180,000. The book value of the exercised warrants was transferred to Share Capital in the amount of \$33,000.

b) Stock options

The Company changed the stock option plan on January 22, 2008. The number of common shares reserved by the Board of Directors for options granted under the plan shall not exceed 10% of the issued and outstanding common shares of the Company. The plan is available to the Company's directors, consultants, officers and employees.

The stock option plan stipulates that the terms of the options and the option price shall be fixed by the directors subject to the price restrictions and other requirements imposed by TSX Venture Exchange. The exercise period cannot exceed five years, beginning on the grant date.

The compensation expense in regards to the stock option plan included in the administrative expenses for the year ended August 31, 2008 is \$252,576 (\$345,368 for the year ended August 31, 2007).

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

12. Share capital, stock-options and warrants (continued)

b) Stock options (continued)

The fair value of these options was determined using the Black-Scholes option pricing model with the following assumptions:

Risk-free interest rate	Between 2.98% and 4.15%
Expected volatility	Between 70% and 95%
Expected dividend yield on shares	- %
Duration	5 years
Fair value per option at the grant date	Between \$0.22 and \$0.70

The Black-Scholes options valuation model was developed to estimate the fair value of traded options, which have no vesting restrictions and are fully transferable, a practice which differs significantly from the Company's stock option awards. In addition, option valuation models require the input of highly-subjective assumptions including the expected stock price volatility. Any changes in the subjective input assumptions can affect the fair value estimate.

The situation of the outstanding stock option plan and the changes that took place during the years ended August 31, 2007 and 2008 are as follows:

	2008		2007	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
		\$		\$
Outstanding at beginning of year	2,033,333	0.53	-	-
Options assumed following the qualifying transaction with DCB Capital Inc.	-	-	333,333	0.30
Options granted	912,500	0.77	1,700,000	0.57
Options cancelled	(295,000)	0.58	-	-
Options exercised	(408,333)	0.34	-	-
Outstanding at end of the year	2,242,500	0.65	2,033,333	0.53
Options exercisable at end of the year	765,000	0.59	833,333	0.46

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

12. Share capital, stock-options and warrants (continued)

b) Stock options (continued)

The table below provides information on the outstanding stock options as at August 31, 2008:

Exercise price	Number of outstanding stock options	Number of exercisable stock options	Weighted average residual duration (years)
\$			
0.45	50,000	12,500	3.26
0.50	1,050,000	562,500	3.09
0.60	20,000	-	4.99
0.72	500,000	-	4.28
0.80	150,000	100,000	3.91
0.87	272,500	40,000	4.64
0.95	200,000	50,000	3.62
	2,242,500	765,000	3.67

c) Warrants

The fair value of the warrants was determined using the Black-Scholes option pricing model with the following assumptions:

	Units issued	Commission paid
Exercisable price	\$0.55 and \$0.60	\$0.40 and \$0.80
Risk-free interest rates	From 2.72% to 4.04%	From 2.72 to 4.04%
Expected volatility	From 70% to 76%	From 70% to 76%
Expected dividend yield on shares	- %	- %
Duration	2 years	2 years
Fair value by warrant	\$0.11, \$0.15 and \$0.28	\$0.16 and \$0.35

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

12. Share capital, stock-options and warrants (continued)

c) Warrants (continued)

The situation of the outstanding warrants and the changes that took place during the years ended August 31, 2007 and 2008 are as follows:

	2008		2007	
	Number of warrants	Weighted average exercise price \$	Number of warrants	Weighted average exercise price \$
Outstanding at beginning of year	6,902,722	0,58	-	-
Warrants issued on October 3, 2006 in relation with the private placement (Note 12 a)v)	-	-	2,600,000 208,000	0.60 0.40
Warrants issued on October 10, 2006 in relation with the private placement (Note 12 a)vi)	-	-	2,937,500 235,000	0.60 0.40
Warrants issued on December 5, 2006 in relation with the private placement (Note 12 a)vii)	-	-	1,222,222	0.55
Warrants exercised	-	-	(300,000)	0.60
Warrants exercised during the period (Note 12a)i)	(1,483,611)	0.56	-	-
Warrants issued, private placement (Note 12a)ii)	2,355,563	1.10	-	-
Warrants issued, private placement (Note 12a)ii)	329,779	0.80	-	-
Outstanding at end of year	8,104,453	0.74	6,902,722	0.58
Warrants exercisable at end of year	8,104,453	0,74	6,902,722	0.58

The table below provides information on the outstanding warrants as at August 31, 2008:

Exercise price \$	Number of outstanding warrants	Number of exercisable warrants	Weighted average residual duration (years)
0.40	443,000	443,000	0.10
0.55	111,111	111,111	0.26
0.60	4,865,000	4,865,000	0.10
0.80	329,779	329,779	1.60
1.10	2,355,563	2,355,563	1.60
	8,104,453	8,104,453	0.60

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

13. Loss per share

The table below presents a reconciliation between the basic net loss and the diluted net loss per share:

	2008	2007
	\$	\$
Numerator		
Net loss	(1,336,688)	(2,313,018)
Amount available for calculating the loss per share	(1,336,688)	(2,313,018)
Denominator		
Number of shares		
Weighted average number of shares outstanding	36,327,185	30,819,163
Dilutive effect of stock options and warrants	-	-
Weighted average number of shares outstanding on diluted basis	36,327,185	30,819,163
Amount per share		
Net loss per share		
Basic	(0.04)	(0.08)
Diluted	(0.04)	(0.08)

The calculation of dilution effects excludes options and warrants that have an anti-diluting effect.

However, should the Company's basic earnings per share have been positive, some options and warrants, at an exercise price of \$0.30, \$0.40, \$0.45, \$0.50, \$0.55, \$0.60, \$0.72, \$0.80 and \$0.87, would have been dilutive and would have resulted in the addition of 2,434,422 shares to the weighted average number of shares outstanding used in the diluted earnings per share calculation for year ended August 31, 2008 (1,544,293 as at August 31, 2007).

Opsens Inc.

Notes to the Consolidated Financial Statements August 31, 2008 and 2007

14. Additional information on the Statements of Cash Flows

	2008	2007
	\$	\$
<i>Changes in non-cash operating working capital items (net of effects of the business acquisition)</i>		
Accounts receivable	(584,425)	69,113
Income tax credits receivable	(6,595)	299,795
Inventories	(78,450)	(192,869)
Work in progress	(237,551)	-
Prepaid expenses	(66,837)	(12,770)
Accounts payable and accrued liabilities	181,867	22,609
Deferred revenue	(20,000)	-
	(811,991)	185,878

Cash and cash equivalents

Cash	147,574	84,063
Short-term investments	3,594,946	1,755,316
	3,742,520	1,839,379

Other information

Interests paid	56,283	56,343
----------------	---------------	--------

Non-cash transactions

The Company concluded the acquisition of all outstanding shares of Inflo Solutions Inc. ("Inflo") by the issuance of 1,199,997 Opsens common shares with a book value of \$525,574.

On April 8, 2008, Opsens issued broker compensation warrants entitling the Agents to purchase 329,779 common shares of Opsens at an exercise price of \$0.80 per share for a book value of \$117,005.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

15. Commitments

Lease

The Company leases offices under an operating lease expiring on January 31, 2014. This agreement is renewable for an additional five-year period. Future rent, without considering the escalation clause, will amount to \$640,604.

Opsens Solutions rents an office in Alberta with respect to a letter agreement. A lease should be signed in the next quarter in order to finalize a verbal commitment. In case the lease is not signed, the company is committed to pay the monthly lease payments until September 30, 2008. As a result, future lease payments will amount to \$4,478.

Opsens Solutions rents a vehicle under an operating lease expiring in November 2010. Future rent payments will amount to \$18,945.

The Company is committed to purchase an equipment for \$62,885.

Future payments for the leases and other commitments, totalizing \$1,068,241, required in each of the next five years are as follows:

	\$
2009	372,239
2010	214,443
2011	184,628
2012	121,023
2013	121,523
Thereafter	54,385

Licence

Under an exclusive licence with a third party, the Company is committed to provide exclusive marketing of some of its products for a defined territory.

16. Contractual guarantees

During the normal course of business, the Company replaces defective parts under warranties offered at the sale of the products. The term of the warranties is 12 months. During the year ended August 31, 2008, the Company recognized an expense of \$3,688 (\$4,609 for the year ended August 31, 2007) for guarantees. A provision for \$20,000 (\$16,312 as at August 31, 2007) was recorded for guarantees. This provision estimate is based on past experience and is presented in liabilities under "Accounts payable and accrued liabilities." The actual costs that the Company may incur, as well as the moment when the parts should be replaced, can differ from the estimated amount.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

17. Government assistance

Under an agreement reached with Ministère du Développement économique, de l'Innovation et de l'Exportation, the Company received non-refundable contributions to cover some of its incurred costs for hiring an employee and for training. During the year ended August 31, 2008, the Company received a cash contribution of \$4,699 which was recorded against marketing expenses.

During the year ended August 31, 2007, the Company received a cash contribution of \$17,315 from Emploi Québec. Of this amount, \$12,105 was recorded against research and development expenses and \$5,210 against administrative expenses.

18. Income taxes

The effective income tax rate of the Company differs from the rate that would have been calculated using the combined statutory tax rate (federal and provincial). The difference is generated as follows:

	2008	2007
	\$	\$
Income tax recovery using the combined federal and provincial statutory tax rate	(411,847)	(717,834)
Non-deductible expenses	88,566	116,854
Deductible financing fees	(57,801)	(46,466)
Non-taxable income tax credits	(18,123)	(16,684)
Losses carried forward	399,205	664,130
Income tax using effective income tax rate	-	-

As at August 31, 2008, the Company has tax losses of approximately \$3,186,000 for federal purposes and \$3,133,500 for provincial purposes that can be used to reduce future taxable income. These losses expire as follows:

	Federal	Provincial
	\$	\$
2009	380,000	340,000
2013	96,000	121,000
2023	483,000	463,000
2024	42,000	40,000
2025	400	400
2027	1,524,000	1,508,000
2028	660,600	661,100
	3,186,000	3,133,500

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

18. Income taxes (continued)

The Company also has undeducted research and development expenses in the amount of \$1,747,000 for federal purposes and \$2,629,000 for provincial purposes that are deferred over an undetermined period.

Future income tax assets related to tax losses, undeducted research and development expenses, and the difference between the undepreciated capital cost for tax purposes and the net book value of property, plant and equipment will be recorded in the financial statements once the Company concludes that these losses and tax benefits will likely be realized.

Loss of private company status for purposes of income tax credits for scientific research and experimental development

Following the qualifying transaction described in Note 1, Opsens has lost its private company status and, consequently, income tax credits for scientific research and experimental development have been reduced by half. Also, the federal government credits are no longer reimbursable, but can be used only to compensate for income taxes otherwise payable.

19. Income tax credits for scientific research and experimental development

For tax purposes, research and development expenses are detailed as follows:

	2008	2007
	\$	\$
Federal	1,175,000	1,048,000
Provincial	597,000	569,000

These expenses have enabled the Company to become eligible for scientific research and experimental development tax credits reimbursable for the following amounts:

	2008	2007
	\$	\$
Federal	-	41,285
Provincial	158,975	190,473
	158,975	231,758

These credits were recorded in
research and development expenses
in the statements of loss

158,975	231,758
----------------	---------

These credits were recorded
against the related property, plant
and equipment

-	-
---	---

158,975	231,758
----------------	---------

Reimbursable scientific research income tax credits earned for the year ended August 31, 2008 have not yet been reviewed by the taxation authorities, and the amounts granted could differ from those that have been recorded.

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

20. Related party transactions

In the normal course of its operations, the Company has entered into transactions with related parties. These transactions have been measured at the exchange amount.

	2008	2007
	\$	\$
Management fees paid to a shareholder	-	833
Professional fees to a company controlled by a shareholder and director	30,000	35,000
	30,000	35,833

21. Segmented information

Sector's information

The Company's reportable segments are strategic business units managed separately as one is focused on developing, producing, and supplying fiber optic sensors (Opsens Inc.) and the other (Opsens Solutions) is specialized in the commercialization and the installation of optical and conventional sensors for the oil and gas industry.

	2008			2007		
	Opsens inc.	Opsens Solutions	Total	Opsens inc.	Opsens Solutions	Total
	\$	\$	\$	\$	\$	\$
External sales	2,248,817	595,422	2,844,239	813,108	-	813,108
Internal sales	4,000	87,094	91,094	-	-	-
Amortization of property, plant and equipment	94,748	5,507	100,255	71,723	-	71,723
Amortization of intangible assets	20,340	20,000	40,340	29,905	-	29,905
Financial expenses	(71,787)	13,574	(58,213)	(8,861)	-	(8,861)
Net loss	(1,231,708)	(104,980)	(1,336,688)	(2,313,018)	-	(2,313,018)
Acquisition of property, plant and equipment	270,625	44,519	315,144	142,280	-	142,280
Acquisition of intangible assets	37,664	-	37,664	73,661	-	73,661

Opsens Inc.

Notes to the Consolidated Financial Statements August 31, 2008 and 2007

21. Segmented information (continued)

These operating units generate revenue in various geographic segments as follows:

	2008	2007
	\$	\$
Revenue per geographic sector		
Canada	651,875	27,047
United States	933,916	315,883
Germany	416,805	228,538
United Kingdom	285,465	49,994
Other	556,178	191,646
	2,844,239	813,108

Revenues are attributed to the geographic sector based on the clients' location.

Capital assets, which include property, plant and equipment and intangible assets, are all located in Canada.

During the year ended August 31, 2008, revenues from three clients represent individually more than 10% of the total revenues of the Company, i.e. approximately 18.09% (Opsens Solutions' reportable segment), 17.62% (Opsens Inc.'s reportable segment) and 13.09% (Opsens Inc.'s reportable segment). For the year ended August 31, 2007, revenues from one client represented 28.11% of the Company's total revenues.

22. Additional information to the Statements of Loss

	2008	2007
	\$	\$
Government assistance	(4,699)	(17,315)
Income tax credits for research and development	(158,975)	(231,758)
Interest and bank charges	13,174	19,225
Interest on demand loan and long-term debt	48,964	44,195
(Gain) loss on foreign currency translation	(32,809)	14,013
Interest income	(87,541)	(86,292)

Opsens Inc.

Notes to the Consolidated Financial Statements

August 31, 2008 and 2007

23. Financial instruments

Credit risk

The Company provides credit to its customers in the normal course of business. Credit evaluations are performed on an ongoing basis of all its accounts receivable and an allowance for doubtful accounts is recorded when those accounts are deemed uncollectible. Two major customers represent 49% of the Company's accounts receivable as at August 31, 2008.

Interest rate and cash flow risk

The Company is exposed to interest rate fluctuations on the demand loan and certain long-term debt that bears interest at variable rates. The Company does not actively manage this risk.

Foreign exchange risk

The Company realizes certain sales and partnership revenue and purchases certain supplies and professional services in US dollars. Therefore, it is exposed to foreign currency fluctuations. The Company does not actively manage this risk.

Fair value

The fair value of cash and cash equivalents, accounts receivable, income tax credits receivable and accounts payable and accrued liabilities approximate their carrying value due to their short-term maturities.

The fair value of long-term debt is based on the discounted value of future cash flows under the current financial arrangements at the interest rate the Company expects to currently negotiate for loans with similar terms and conditions and maturity dates. The fair value of long-term debt approximates its carrying value due to the current market rates.

24. Subsequent events

On October 3, 2008, 50,000 warrants entitling its holder to acquire one common share of the Company at a price of \$0.40 per share were exercised for an amount of \$20,000. The book value of the exercised warrants was transferred to Share Capital in the amount of \$8,000.

After year end, 393,000 and 4,865,000 warrants entitling its holder to acquire one common share of the Company at a price of \$0.40 and \$0.60 per share respectively expired.

In addition, the Company granted to some employees a total of 210,000 stock options with an average exercise price of \$0.48 per share.

25. Comparative figures

Certain comparative figures have been reclassified in order to conform to the presentation adopted for the current year.

Opsens Inc.

Shareholder Information

Directors

Pierre Carrier
President, Chief Executive Officer, Chairman

Claude Belleville
Vice President, Medical Devices, Laboratories & Transformers

Gaétan Duplain
Vice President Oil and Gas, President, Opsens Solutions

Bertrand Bolduc
Director

Mario Jacob
Director

Jean Rochette
Director

Denis M. Sirois
Director

Senior Officers

Pierre Carrier
President, Chief Executive Officer, Chairman

Claude Belleville
Vice President, Medical Devices, Laboratories & Transformers

Gaétan Duplain
Vice President Oil and Gas, President, Opsens Solutions

Louis Laflamme, CA
Chief Financial Officer, Corporate Secretary

Corporate Information

Head Office

2014 Cyrille-Duquet St.
Suite 125
Quebec City QC G1N 4N6

Phone: (418) 682-9996
Fax: (418) 682-9939

Opsens Solutions

10456 176th St.
Suite 201
Edmonton AB T5S 1L3

Phone: (780) 930-1777
Fax: (780) 930-2077

Website: www.opsens.com

Investor Relations:

For further information about Opsens Inc. or to be placed on the mailing list for quarterly reports and news releases, please contact Louis Laflamme at the head office address, or louis.laflamme@opsens.com.

Auditors

Samson Bélair Deloitte & Touche
Quebec QC

Stock Exchange Listing

Toronto Venture Exchange Trading Symbol: OPS

Transfer Agent & Registrar

CIBC Mellon
2001, University Street
Suite 1600
Montreal QC H3A 2A6
Phone: (514) 285-3600


Annual Meeting of Shareholders

Tuesday, January 20, 2009
10:30 a.m.
l'Hôtel ALT Quebec
Quebec City, QC

Emerging Leader in Oil Sands Measurement

Opsens is working on projects in several areas of oil and gas, but its near-term focus is the Western Canadian oil sands market, where it sees a huge opportunity. There are more than 80 active in situ oil sands projects in Alberta, and all the major oil and gas companies are involved.

Steam assisted gravity drainage is the most common process for developing in situ reserves. In SAGD, recovery rates are typically somewhere between 30% and 60%. To optimize recovery rates, the operator needs data on temperature and pressure below the surface directly from the producer well, where temperatures may be between 200 and 300 degrees Celsius. Opsens' OPP-W sensors have been proven to meet that need, measuring pressure and temperature up to 300 degrees Celsius.



Our Sensors at Work



• OIL & GAS •

Helping operators optimize production in the Western Canadian oil sands.



• MEDICAL DEVICES •

Partners are developing applications in areas such as cardiac assistance and drug manufacturing.



• LABORATORIES & TRANSFORMERS •

Ensuring components that control systems are unaffected by magnetic interference.
Preventing heating in high-power transformers.



#125, 2014, Cyrille-Duquet St., Quebec City, QC G1N 4N6
T. +1 418.682.9996 F. +1 418.682.9939

#201, 10456, 176th St., Edmonton, AB T5S 1L3
T. +1 780.930.1777 F. +1 780.930.2077

www.opsens.com